Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which
has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will
seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by
physician's choice and compared prospectively to ex vivo drug sensitivity testing results.
Participants will be enrolled and assigned into one of the following treatment arms:
Arm 1: Selinexor + pomalidomide + dexamethasone (SPd)
Arm 2: Selinexor + daratumumab + dexamethasone (SDd)
Arm 3: Selinexor + carfilzomib + dexamethasone (SKd)
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Karyopharm Therapeutics Inc National Cancer Institute (NCI)